$HCM

HUTCHMED (HCM) and GSK (GSK) signed a global licensing deal for HMPL-A830, targeting colorectal, pancreatic, and lung cancers. HUTCHMED received a $110M upfront payment, with potential milestone payments up to $1.3B and tiered royalties. GSK gains worldwide rights outside Greater China, with HUTCHMED leading global Phase I trials starting in H2 2026.

HUTCHMED (China) (NASDAQ:HCM) reported H1 2026 results, with China product sales up 40% driven by Elunate and Sulanda. Ex-US FRUZAQLA sales rose 70%, maintaining full-year revenue guidance of $330M-$450M. R&D expenses increased to $79M, reflecting investments in clinical trials and AI. The company has a cash reserve of $1.4B and is advancing multiple clinical trials. Management highlighted growth opportunities in hematology and immunology fields.

Ionis (IONS) and Milestone (MIST) gained FDA approvals for neurology and cardiology drugs. Biogen (BIIB) and AstraZeneca (AZN) also received regulatory nods for Alzheimer's and cancer treatments. Novavax (NVAX) secured global approvals for its COVID-19 vaccine. TScan (TCRX) and Novartis (NVS) announced job cuts. Novartis (NVS) and HUTCHMED (HCM) struck deals worth up to $3.2B and $1.295B respectively.

ACT Energy, Cascadia Minerals, Condor Energies, Highcliff Metals, Hammond Manufacturing, NiobiumX, NSJ Gold, PrairieSky, Riverside, BioSyent, Surge Energy, Swiss Water, and Total Energy hit 52-week highs. ACT Energy and Swiss Water received TSX approval for share buybacks. Cascadia reported drill results. Condor achieved a production record. PrairieSky reported Q3 revenues of $10.9M and funds from operations of $133.1M. BioSyent, Surge, and Total declared dividends.

Summit Therapeutics (SMMT) shares rose 10.1% to $16.07 after positive Phase III study results. Snowflake (SNOW) gained 20.6% following better-than-expected earnings. HUTCHMED (HCM) rose 13% after a licensing deal. Tesla (TSLA) increased 5.7% to $377.53. Other stocks like Robinhood (HOOD), Coinbase (COIN), and others also saw gains.

Hutchmed (HCM) secured a licensing deal with GSK (GSK), receiving $110M upfront and up to $1.185B in milestones. Panmure and Cavendish reiterated 'buy' ratings, with target prices of 400p and 370p respectively, citing undervalued oncology pipeline and GSK's validation. Hutchmed's shares rose 15% to 205.84p.

Hutchmed (HCM) secured a $1.3bn licensing deal with GSK for HMPL-A830, receiving $110m upfront. Frontier Developments (FDEV) is developing a Disney IP-based game. Blackbird (BIRD) reported accelerated subscriber growth. Jangada Mines (JAN) investees consider flotations. Futura Medical (FUM) raised £1.6m and launched a sales process, share price fell 24.2%.

HUTCHMED shares rose 17% after announcing a licensing deal with GSK for its cancer drug HMPL-A830. The agreement is worth up to $1.3 billion, with HUTCHMED receiving $110 million upfront. GSK gains exclusive rights outside Greater China to develop and commercialize the therapy, which targets colorectal, pancreatic, and lung cancers. HUTCHMED will lead initial Phase I trials, with GSK taking over subsequent development.

HUTCHMED's ATLED® (fanregratinib) received conditional NMPA approval for treating advanced FGFR2-altered intrahepatic cholangiocarcinoma in China. The approval is based on Phase II trial data showing a 42.5% objective response rate. HUTCHMED plans to commercialize the drug, with Phase IIIb trials ongoing.

Phase 3 SAFFRON trial data reported that osimertinib 80 mg daily plus investigational savolitinib 300 mg twice daily improved progression-free survival and overall survival versus doublet platinum chemotherapy in EGFR-mutated, MET-overexpressed/amplified NSCLC after progression on osimertinib. Safety matched known profiles. AstraZeneca and Hutchmed said full results will be presented later.